Paul M. J. McSheehy

Novartis Institutes for Biomedical Research, Switzerland

Paul M. J. McSheehy has been working in oncology research for Novartis Pharma AG in Basel, Switzerland since November 2001. He has been responsible for preclinical research and translational medicine on a novel microtubule stabilizer, patupilone, and the allosteric mTOR inhibitor everolimus. He was also involved in planning and implementation of preclinical functional-imaging experiments performed in Novartis oncology and has published several original manuscripts in this field. He previously worked in industry for Virco UK and SmithKline Beecham, from 2000 to 2001 and from 1991 to 1994, respectively. From 1986 to 1991 and from 1995 to 2000, he served as a Research Fellow in the CRC Biomedical Magnetic Resonance Research Unit at St. George’s Hospital Medical School, London, UK, led by Professor J. R. Griffiths, where he studied tumor biology and pharmacokinetics of anticancer drugs using 19F/31P-MRS and MRI in vivo allied to cell culture and ex vivo biochemical techniques. From 1989 to 1990, he had a one year sabbatical at the Mario Negri Institute in Milan, Italy, where he investigated cell-cycle mechanisms in the action of anticancer drugs. His first postdoctoral post was at St. Bartholomew’s Hospital, London, UK, from 1984 to 1986, where he was investigating hormone stimulation of bone resorption. He completed his Ph.D. degree in 1984 (London) and the B.S. degree in 1980 (University of Sussex) in biochemistry. He has published over 60 original articles or reviews.

Biography Updated on 3 April 2011

Scholarly Contributions [Data Provided by scopus]